Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meningococcal Group C conjugate vaccine (Novartis)
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal Group C conjugate vaccine (specifically Menjugate, originally developed by Chiron and later Novartis) is a vaccine indicated for the active immunization of children from 2 months of age, adolescents, and adults for the prevention of invasive disease caused by *Neisseria meningitidis* serogroup C. The vaccine consists of purified capsular oligosaccharides from the bacteria, which are chemically conjugated to the CRM197 carrier protein (a non-toxic recombinant variant of the diphtheria toxin). This conjugation converts the polysaccharide into a T-cell dependent antigen, allowing for a robust immune response and the induction of immunological memory, even in infants. The vaccine induces the production of bactericidal antibodies that provide protection against meningococcal meningitis and septicemia caused by serogroup C.
- Brand names
- Menjugate
- Other names
- MenC conjugate vaccineNeisseria meningitidis group C conjugate vaccineMenC-CRM197MenC-CRM-197MenC-CRM 197
02
Targets
Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on Meningococcal Group C conjugate vaccine (Novartis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal Group C conjugate vaccine (Novartis).